{"id":816826,"date":"2025-02-24T10:45:37","date_gmt":"2025-02-24T15:45:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/"},"modified":"2025-02-24T10:45:37","modified_gmt":"2025-02-24T15:45:37","slug":"medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/","title":{"rendered":"Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n New closed-loop system self-adjusts DBS therapy to individual brain activity\u00a0<\/i>
\n in real time; the largest commercial launch of brain-computer interface technology ever\u00a0<\/i>\n <\/p>\n

\n GALWAY, Ireland<\/span><\/span>, Feb. 24, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0For the one million people diagnosed with Parkinson’s disease in the United States<\/span>1<\/sup>, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense\u2122 Adaptive deep brain stimulation (aDBS) and BrainSense\u2122 Electrode Identifier (EI).<\/p>\n

There is no cure for debilitating neurological conditions like Parkinson’s, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson’s and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.<\/p>\n

Now Medtronic has enhanced its Percept\u2122 DBS neurostimulators with exclusive BrainSense\u2122 Adaptive technology\u2020<\/sup>, introducing aDBS for people living with Parkinson’s. This feature personalizes therapy based on a patient’s brain activity in real time \u2013 both in clinical settings and in daily life2<\/sup>. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.<\/p>\n

“Medtronic is the only company in the world to offer an adaptive DBS system that dynamically adjusts therapy in real time,” said\u00a0Brett Wall, executive vice president and president of the Medtronic Neuroscience Portfolio. “This new era in Parkinson’s care represents more than a decade of intentional innovation\u2014ushering in personalized neuromodulation at scale that responds to a patient’s changing needs, equipping clinicians with unparalleled insights, and setting a new standard for DBS therapy.”<\/p>\n

For more than ten years, Medtronic has been developing a complete, sensing-enabled DBS system leveraging exclusive BrainSense\u2122 technology to detect, capture, and classify different brain signals, putting Medtronic at the forefront of incorporating brain-computer interface (BCI) technology into DBS therapy. Medtronic considers BCI technology a crucial element for developing innovative products that treat some of the cardinal symptoms of Parkinson’s with specific focus on rehabilitation and restoring health. BrainSense\u2122 Adaptive DBS is available to Medtronic DBS patients with Parkinson’s who have been implanted with a Percept\u2122 neurostimulator, as well as future Medtronic DBS patients. With more than 40,000 DBS patients served worldwide3<\/sup> with Medtronic Percept\u2122 devices, BrainSense\u2122 Adaptive DBS presents the largest commercial launch (by several magnitudes) of BCI technology \u2013 ever.\u00a0<\/p>\n

“Adaptive deep brain stimulation will help revolutionize the approach to therapeutic treatment for patients with Parkinson’s disease,” said Helen Bronte-Stewart MD MSE, FAAN, FANA, John E. Cahill Family Professor in the department of Neurology and Neurological Sciences and Director of the Human Motor Control and Neuromodulation Lab at Stanford University<\/span> School of Medicine. “The transformative personalized care we can achieve through automatic adjustment greatly benefits patients receiving therapy that adapts to their evolving needs.”<\/p>\n

The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice. Dr. Bronte-Stewart served as the global principal investigator for the trial, which was conducted as an international, multi-center, prospective, single-blind, randomized crossover study (between two modes of aDBS), and evaluated the safety and effectiveness of chronic dual- and single-threshold aDBS modes compared to continuous DBS (cDBS) for eligible patients with Parkinson’s disease receiving DBS therapy. This study represents the largest and longest assessment of aDBS conducted in both clinical and home settings and was developed in collaboration with more than a dozen world-renowned neurologists and neurosurgeons from leading academic institutions across the globe including Stanford University<\/span> School of Medicine, University of California San Francisco<\/span>, Massachusetts<\/span> General Hospital and Amsterdam University Medical Center. The study methodology and sensing data from the study were published in npj Parkinson’s Disease<\/a><\/i>, a journal within the prestigious Nature Portfolio.<\/p>\n

“For patients who struggle with motor symptom fluctuations, dyskinesias, and other side effects with cDBS, aDBS may offer improved symptom control,” said Todd Herrington<\/span>, MD, PhD, director of the Deep Brain Stimulation Program at Massachusetts<\/span> General Hospital, assistant professor of neurology at Harvard Medical School<\/span>, and investigator for the ADAPT-PD trial. “Approval of this therapy represents an important step forward for patients and I look forward to seeing the ADAPT-PD study results published soon.”<\/p>\n

“Our BrainSense technology provides unique and clinically important insights that no other DBS system can offer, using a person’s own brain signals to provide a window into their condition, in real time, over time,” said Paolo Di Vincenzo<\/span>, president of the Neuromodulation business, which is part of the Neuroscience Portfolio at Medtronic. “Our focus has always been on creating solutions that work for real lives, not just standalone symptoms. aDBS reflects that commitment, bringing a new expectation in Parkinson’s treatment.”<\/p>\n

The U.S. FDA approval also includes the Medtronic BrainSense\u2122 Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. By using EI, clinicians can conduct an accurate and precise initial programming, 85% faster compared to traditional electrode selection 4<\/sup>.<\/p>\n

“BrainSense\u2122 Electrode Identifier offers less ambiguity and greater efficiency compared to the traditional method of electrode selection by providing a personalized, real-time snapshot of a patient’s brain signals, which can help provide insights into the proximal sweet spot for programming. This new method reduces initial contact selection time, streamlining the process and ensuring more precise, tailored therapy for each patient,” said Drew Kern<\/span>, MD, MS, neurologist and associate professor of neurology at the University of Colorado<\/span> School of Medicine.<\/p>\n

“Our dedication to advancing DBS research and innovation has transformed therapeutic options for individuals with movement disorders and epilepsy,” said Amaza Reitmeier<\/span>, vice president and general manager, Neuromodulation portfolio at Medtronic. “With this FDA approval, which quickly followed our CE Mark, we are taking another significant step forward in delivering sensing-enabled personalized treatments to people with Parkinson’s.”<\/p>\n

BrainSense\u2122 aDBS and EI are also available<\/a> in Europe<\/span>. Patient programmings in the United States<\/span> will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months.<\/p>\n

Since 1987, Medtronic has served more than 185,000 people with movement disorders and other indications in more than 70 countries with its life-changing cDBS therapy3<\/sup>. Patients considering DBS therapy should discuss treatment options with their healthcare provider. To learn more about Medtronic DBS with BrainSense\u2122 technology, visit our website<\/a>.\u00a0<\/p>\n

\n
\n About Medtronic
<\/u>
\n <\/b>Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland<\/span>, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission<\/span> \u2014 to alleviate pain, restore health, and extend life \u2014 unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com<\/a>\u00a0and follow Medtronic on LinkedIn<\/a>.<\/p>\n

\n Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.<\/b>\n <\/p>\n

\n \u2020<\/sup>The sensing feature of the Percept\u2122 PC and Percept\u2122 RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status.<\/p>\n

\n References<\/b>\n <\/p>\n

    \n
  1. Parkinson’s Foundation. (2025).\u00a0Statistics: Get informed about Parkinson’s disease with these key numbers.<\/i> Retrieved from https:\/\/www.parkinson.org<\/a>.<\/li>\n
  2. Stanslaski S, Summers RLS, Tonder L, et al. Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) clinical trial. NPJ Parkinsons Dis. 2024;10(1):174.<\/li>\n
  3. Medtronic data on file.\u00a0<\/li>\n
  4. Thompson, J.,\u00a0Radcliffe, E., Ojemann, S.,et al. Monopolar sensing improves the efficiency of DBS programming in Parkinson’s disease [abstract]. Mov Disord<\/i>. 2024; 39 (suppl 1). https:\/\/www.mdsabstracts.org\/abstract\/monopolar-sensing-improves-the-efficiency-of-dbs-programming-in-parkinsons-disease\/<\/a>. Accessed 01\/29\/25<\/span><\/li>\n<\/ol>\n
    \n\n\n\n\n\n
    \n

    \n
    \n Contacts:<\/u>
    \n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

    \n

    \n Naomi Rodiles\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/span>\n <\/p>\n<\/td>\n

    		\n

    \n Ryan\u00a0Weispfenning<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

    \n

    \n Public Relations\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/span>\n <\/p>\n<\/td>\n

    		\n

    \n Investor Relations<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

    \n

    \n +1-612-427-5521\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/span>\n <\/p>\n<\/td>\n

    		\n

    \n +1-763-505-4626<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

    \n

    \n
    \n \"(PRNewsfoto\/Medtronic
    \n <\/a>\n <\/p>\n<\/p><\/div>\n

    <\/div>\n

    \n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/medtronic-earns-us-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons-302382890.html<\/a><\/p>\n

    SOURCE Medtronic plc<\/p>\n<\/p><\/div>\n

    \"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

    PR Newswire New closed-loop system self-adjusts DBS therapy to individual brain activity\u00a0 in real time; the largest commercial launch of brain-computer interface technology ever\u00a0 GALWAY, Ireland, Feb. 24, 2025 \/PRNewswire\/ —\u00a0For the one million people diagnosed with Parkinson’s disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense\u2122 Adaptive deep brain stimulation (aDBS) and BrainSense\u2122 Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson’s, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson’s and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a … <\/p>\n

    Continue reading “Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816826","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMedtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire New closed-loop system self-adjusts DBS therapy to individual brain activity\u00a0 in real time; the largest commercial launch of brain-computer interface technology ever\u00a0 GALWAY, Ireland, Feb. 24, 2025 \/PRNewswire\/ —\u00a0For the one million people diagnosed with Parkinson’s disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense\u2122 Adaptive deep brain stimulation (aDBS) and BrainSense\u2122 Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson’s, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson’s and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a … Continue reading "Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T15:45:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1657690\/Medtronic_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s\",\"datePublished\":\"2025-02-24T15:45:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/\"},\"wordCount\":1396,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1657690\\\/Medtronic_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/\",\"name\":\"Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1657690\\\/Medtronic_Logo.jpg\",\"datePublished\":\"2025-02-24T15:45:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1657690\\\/Medtronic_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1657690\\\/Medtronic_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/","og_locale":"en_US","og_type":"article","og_title":"Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Market Newsdesk","og_description":"PR Newswire New closed-loop system self-adjusts DBS therapy to individual brain activity\u00a0 in real time; the largest commercial launch of brain-computer interface technology ever\u00a0 GALWAY, Ireland, Feb. 24, 2025 \/PRNewswire\/ —\u00a0For the one million people diagnosed with Parkinson’s disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense\u2122 Adaptive deep brain stimulation (aDBS) and BrainSense\u2122 Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson’s, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson’s and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a … Continue reading \"Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T15:45:37+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1657690\/Medtronic_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s","datePublished":"2025-02-24T15:45:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/"},"wordCount":1396,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1657690\/Medtronic_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/","name":"Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1657690\/Medtronic_Logo.jpg","datePublished":"2025-02-24T15:45:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1657690\/Medtronic_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1657690\/Medtronic_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-people-with-parkinsons\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Medtronic earns U.S. FDA approval for the world’s first Adaptive deep brain stimulation system for people with Parkinson’s"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816826"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816826\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}